The Therapeutic Peptide Landscape: A Critical Evidence Revie…The Therapeutic Peptide Landscape: A Critical Evidence Review

Abstract

Therapeutic peptides have moved from the margins of sports and longevity medicine into mainstream clinical conversation, propelled by social media, the GLP-1 weight-loss boom and a broad cultural normalisation of self-injection. Yet the evidence underpinning the most widely promoted compounds is strikingly uneven. This review surveys eleven peptides frequently encountered in aesthetic, regenerative and wellness practice — BPC-157, TB-500 (thymosin β4), thymosin α1, sermorelin, CJC-1295, ipamorelin, tesamorelin, GHK-Cu, MOTS-c, selank and semax — grading each by the quality of its human evidence and its regulatory standing. The picture that emerges is a spectrum: a small number of peptides hold genuine regulatory approval and Phase III data, a larger group rests almost entirely on preclinical or topical evidence, and several sit in a contested regulatory grey zone now under active MHRA scrutiny. For practitioners, the central message is that promise and proof are not the same thing.

Method and framing

This is a narrative review intended for clinical education, not a treatment protocol. A simple evidential hierarchy is applied throughout: approved (a licensed medicine in at least one major jurisdiction with supporting trial data), clinical (human trial data exists but the agent is not approved for the indication discussed), topical/observational (human data limited to topical use or to associative physiology), and preclinical (evidence confined to cell and animal models). Doses cited are those reported in published trials and are included only to characterise the evidence, not as guidance for administration.

Tissue repair and regeneration

BPC-157 Unapproved / under review

BPC-157 ("Body Protection Compound-157") is a synthetic 15-amino-acid sequence derived from a protein found in human gastric juice. Preclinically it is genuinely interesting: across numerous rodent models it has shown cytoprotective and pro-healing effects in the gastrointestinal tract, tendon, ligament, muscle and bone, apparently by upregulating growth-hormone receptor expression, promoting angiogenesis and modulating the nitric-oxide system while dampening inflammatory cytokines.

The problem is translation. A 2025 systematic review of the orthopaedic literature (Vasireddi and colleagues) screened 544 articles and found that only one clinical study met inclusion criteria; the remaining studies were preclinical. A parallel systematic review of the gastrointestinal literature reached the same conclusion — robust mechanistic and animal data, essentially no controlled human evidence, and no clinical safety data. The peptide's half-life in humans is under 30 minutes. As of 2026 there are no published, peer-reviewed, randomised controlled human trials demonstrating efficacy or safety for any indication, and a planned Phase I safety study (NCT02637284) was never published.

BPC-157 was banned by the World Anti-Doping Agency in 2022. Because it promotes angiogenesis, theoretical concerns about tumour promotion remain unresolved. It is not approved by any medicines regulator, and was the first peptide the MHRA named in its 2026 review. The honest summary: a compelling preclinical story with a near-empty human evidence base — a candidate worth a proper trial, not a validated therapy.

TB-500 / thymosin β4 Preclinical only

Thymosin β4 (Tβ4) is a 43-amino-acid actin-sequestering protein found in almost every cell, central to cell migration, angiogenesis and tissue repair. "TB-500" is the name used in the research-peptide market for a synthetic fragment marketed as functionally equivalent. In animal models Tβ4 is among the most active wound-healing molecules studied: foundational work by Malinda and colleagues (1999) showed accelerated re-epithelialisation in rodent wounds, with subsequent effects demonstrated on corneal repair, hair-follicle regeneration and post-infarct cardiac remodelling.

Human evidence exists but is confined largely to the full molecule. RegeneRx Biopharmaceuticals advanced Tβ4 through Phase II trials for chronic pressure and venous-stasis ulcers and for dry-eye disease (RGN-259), reporting accelerated healing in responders (Goldstein and colleagues, 2012) without progression to Phase III. The synthetic "TB-500" fragment used in sports and longevity settings has no randomised human trials supporting its musculoskeletal claims; those uses are anecdotal. It is WADA-prohibited and unapproved for human therapeutic use.

GHK-Cu Topical / observational

The copper tripeptide glycyl-L-histidyl-L-lysine (GHK), complexed with copper as GHK-Cu, is the most evidence-supported peptide in this review for cosmetic use — provided the route is topical. First isolated from human plasma by Pickart in 1973, GHK declines with age and stimulates synthesis of collagen, elastin and glycosaminoglycans while supporting wound repair and fibroblast function.

Human topical data are reasonably encouraging. In a comparative biopsy study, Abdulghani and colleagues (1999) reported that a GHK-Cu cream increased collagen in roughly 70% of treated women, outperforming both vitamin C and retinoic acid creams. Twelve-week facial and periorbital trials (Leyden and colleagues) found improvements in firmness, density, fine lines and mottled pigmentation. The evidence is not uniformly positive: a randomised study after CO₂ laser resurfacing found no objective improvement in wrinkles or erythema, though patient satisfaction was higher. A mechanistic caveat persists — some work suggests the collagen-stimulating effect may derive substantially from the copper ion itself rather than the peptide. Injectable use is off-label and far less studied.

Immune modulation

Thymosin α1 Approved

Thymosin α1 (thymalfasin) is a 28-amino-acid peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein and colleagues in the 1970s. It is a true immunomodulator, augmenting T-cell function and shifting immune balance, and it is the one compound in this review with genuine pharmaceutical pedigree. Marketed as Zadaxin, it is approved in approximately 35 countries — notably for chronic hepatitis B and as a vaccine adjuvant — though it is not FDA-approved in the United States. Its evidence base is deep relative to its peers: Phase III programmes (including a randomised trial of more than 550 patients in chronic hepatitis C as add-on to peginterferon and ribavirin), plus studies in severe sepsis, certain malignancies and, during the pandemic, COVID-19. Post-marketing experience spans hundreds of thousands of patients with a favourable tolerability profile. In the UK it remains unlicensed and was named in the MHRA review, but on the international evidence it is the best-validated peptide discussed here.

The growth-hormone axis

These four peptides share a mechanism — stimulating the body's own pulsatile growth-hormone (GH) release rather than supplying exogenous GH — but they differ sharply in evidence and legality. All are prohibited in sport under WADA category S2.

Tesamorelin Approved

Tesamorelin is a stabilised analogue of growth-hormone-releasing hormone (GHRH). It is FDA-approved (Egrifta, 2010) for the reduction of excess visceral abdominal fat in HIV-associated lipodystrophy — the only approved indication of any peptide in this group. Approval rested on two pivotal Phase III randomised trials (Falutz and colleagues) enrolling roughly 800 patients, in which 2 mg daily reduced visceral adipose tissue by approximately 15% over 26 weeks versus placebo, alongside reductions in triglycerides. Effects reverse on discontinuation, and long-term cardiovascular outcome data remain limited. The formulation has since been updated (Egrifta SV in 2019; the concentrated F8 formulation, Egrifta WR, approved March 2025). Off-label interest in non-HIV visceral fat, hepatic steatosis and cognition is growing but is not the basis of its approval.

Sermorelin Clinical evidence

Sermorelin is GHRH(1–29), the first 29 amino acids of GHRH, which retain full GH-releasing activity. It was FDA-approved as Geref in the 1990s — first as a diagnostic for pituitary GH capacity and subsequently for paediatric GH deficiency, with paediatric trial data (Thorner and colleagues, 1996) showing meaningful height-velocity gains. The branded product was withdrawn in 2008 for commercial, not safety, reasons. It is now widely prescribed off-label through compounding pharmacies for adult "GH optimisation," sleep and recovery, despite the original approval being paediatric. Its very short half-life (~12 minutes) limits its pharmacology.

CJC-1295 Preclinical only

CJC-1295 is a GHRH analogue available in two forms: with a drug-affinity complex (DAC) that binds albumin and extends its half-life to several days, and without DAC ("modified GRF 1-29"). A Phase I study (Walker, Teichman and colleagues, 2006, JCEM) demonstrated sustained, dose-dependent rises in GH and IGF-1 lasting several days after a single injection in healthy adults, with no serious adverse events at the doses tested. Beyond these early pharmacodynamic studies there are no controlled trials demonstrating clinical outcomes (body composition, function, safety over time). It is frequently paired with ipamorelin on the rationale of complementary mechanisms.

Ipamorelin Preclinical only

Ipamorelin is a synthetic pentapeptide described by Raun and colleagues (1998) as "the first selective growth-hormone secretagogue," developed within Novo Nordisk. It acts on the ghrelin receptor (GHS-R1a) to trigger GH release; its defining feature is selectivity, producing minimal cortisol or prolactin elevation and, at research doses, little appetite stimulation. This clean pharmacological profile made it the preferred GHRP-class partner in modern stacks. Despite the attractive mechanism, formal clinical development was not carried through to approval, and human outcome data are sparse.

Metabolic and mitochondrial signalling

MOTS-c Unapproved / under review

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA gene — part of a paradigm-shifting class of "mitochondrial hormones." Its discovery (Lee and colleagues, 2015, Cell Metabolism) showed that MOTS-c promotes metabolic homeostasis, enhances glucose utilisation via AMPK-dependent pathways, and reduces obesity and insulin resistance in mice. Subsequent work (Reynolds and colleagues, 2021, Nature Communications) established it as exercise-induced and showed that intermittent treatment improved physical capacity and healthspan in aged mice. Human data exist but are observational: endogenous MOTS-c rises markedly in skeletal muscle and circulation with exercise and declines with age and in type 2 diabetes (Ramanjaneya and colleagues, 2019). What does not yet exist is any human therapeutic trial of administered MOTS-c. Its biology is among the most scientifically exciting in this review; its clinical evidence in people is nil. It was named in the MHRA review.

Neuroactive peptides

Selank and semax occupy a distinctive position: both carry genuine regulatory approval — but only in Russia, and the supporting literature is largely Russian-language and not independently replicated in the West.

Selank Clinical evidence

Selank is a synthetic heptapeptide analogue of the immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It was registered by the Russian Ministry of Health in 2009 as an anxiolytic and nootropic nasal preparation. The most-cited human study (Zozulia and colleagues, 2008) compared Selank with the benzodiazepine medazepam in generalised anxiety disorder and neurasthenia, reporting comparable anxiolytic efficacy with additional anti-asthenic effects and — importantly — without the sedation, cognitive impairment or dependence associated with benzodiazepines. Proposed mechanisms include GABAergic and serotonergic modulation and effects on enkephalin degradation. No FDA or EMA-registered trials exist.

Semax Clinical evidence

Semax is a synthetic heptapeptide based on the ACTH(4–10) fragment, engineered to retain central nervous-system activity while shedding the parent hormone's endocrine effects. Developed at the same institute, it is registered in Russia for ischaemic stroke, transient ischaemic attack, cognitive disorders following head injury and optic-nerve pathology, and appears on Russia's List of Vital and Essential Medicines (added 2011) — an unusual credential for a nootropic. Its signature mechanism is rapid upregulation of brain-derived neurotrophic factor (BDNF) and TrkB signalling, well replicated in animals, with Russian clinical trials reporting improved neurological recovery in ischaemic stroke when given within the therapeutic window.

Evidence at a glance

Clinical and regulatory considerations

First, the evidence gradient is steep. Two peptides (thymosin α1 and tesamorelin) carry Phase III data and approval; sermorelin has a genuine but historic and paediatric approval; selank and semax are approved only within one regulatory system whose evidence Western bodies have not adopted. The remainder — BPC-157, TB-500, CJC-1295, ipamorelin and MOTS-c — rest on preclinical, early-phase or purely observational data. The popularity of a peptide online correlates poorly with the strength of its human evidence; BPC-157 is the clearest example of marketing outpacing proof.

Second, the UK regulatory position is now active, not theoretical. The MHRA's 2026 review makes clear that offering peptide injections with medicinal claims converts them into medicines under the Human Medicines Regulations 2012, exposing clinics to enforcement. Lynda Scammell of the MHRA noted that peptides may fall under cosmetic, supplement or medicines frameworks depending on intended purpose, and that unsubstantiated claims are disregarded. The US picture is evolving separately, with proposed reclassification of several peptides under the FDA's 503A compounding categories reported in early 2026; this does not alter UK law.

Third, "natural" is not "safe." A recurring justification — that BPC-157 is derived from a protein in gastric juice, or that MOTS-c is endogenous — does not establish safety at pharmacological doses, by injection, over time. Endogenous peptides act locally and at physiological concentrations; exogenous administration is a different proposition, and for most peptides here the long-term human safety record simply does not exist. Product quality is a further hazard: grey-market peptides are frequently mislabelled or contaminated.

The HSI verdict

References

1. Vasireddi N, Hahamyan HA, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal / SAGE, 2025.
2. Systematic review of oral BPC-157 in gastrointestinal disease (PRISMA), American Journal of Gastroenterology (ACG abstract S808), 2025.
3. Malinda KM, Sidhu GS, Mani H, et al. Thymosin β4 accelerates wound healing. J Invest Dermatol, 1999.
4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther, 2012.
5. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. Cosmetics (MDPI), 2018.
6. Abdulghani AA, et al. Effects of topical creams containing GHK-Cu, vitamin C and retinoic acid on collagen production. 1999.
7. Leyden J, et al. Skin care benefits of copper peptide containing facial and eye creams (12-week trials).
8. CO₂ laser resurfacing and topical GHK-Cu randomised study, Archives of Facial Plastic Surgery.
9. Goldstein AL, et al. Thymosin α1 (thymalfasin): isolation and immunomodulatory activity; Zadaxin Phase III chronic hepatitis C trial (NCT01178996, sigma-tau).
10. Falutz J, et al. Tesamorelin for the reduction of visceral fat in HIV-associated lipodystrophy. FDA approval of Egrifta (2010); Egrifta WR/F8 (2025).
11. Thorner M, et al. Sermorelin (GHRH 1-29) in growth hormone deficiency. JCEM, 1996; FDA Geref labelling.
12. Walker RF, Teichman SL, et al. Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults. JCEM, 2006.
13. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol, 1998.
14. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab, 2015.
15. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline. Nat Commun, 2021.
16. Ramanjaneya M, et al. Mitochondrial-derived peptides are down-regulated in diabetes. 2019.
17. Zozulia AA, et al. Efficacy and safety of selank in GAD and neurasthenia. Zh Nevrol Psikhiatr, 2008.
18. Reviews of semax (ACTH 4-10 analogue), BDNF upregulation and ischaemic stroke outcomes; Russian List of Vital and Essential Medicines (2011).
19. MHRA statement on peptide clinics, April 2026 (The Guardian investigation; Human Medicines Regulations 2012).
20. World Anti-Doping Agency Prohibited List (category S2; BPC-157 added 2022).

Disclaimer: This review is provided for professional education and does not constitute medical advice or an endorsement of any unlicensed therapy. Several peptides discussed are not authorised for human use in the UK and may not be marketed or supplied with medicinal claims.